Worth reading
90Important
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of warrants by third-party allotment (Series 15 warrants and Series 16 warrants)
発行・処分する株式数
Series 15 warrants: 7,000,000 shares; Series 16 warrants: 16,400,000 shares (all warrants fully exercised)
Amount of funds to be raised
Series 15 warrants: ¥398 million; Series 16 warrants: ¥1,463 million. Estimated net proceeds: Not disclosed
Specific use of funds
Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failureAmount ¥226 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures October 2019 to September 2021
Development expenses for regenerative medicine products, including glycan-modified T cellsAmount ¥100 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures October 2020 to July 2025
Expenses related to the development of regenerative medicine productsAmount ¥71 million (unallocated amount as of 28 February 2026: ¥50 million) / Scheduled timing of expenditures August 2025 to September 2027
Expenses related to the development of regenerative medicine productsAmount ¥551 million (unallocated amount as of 28 February 2026: ¥551 million) / Scheduled timing of expenditures August 2025 to September 2027
Expenses related to the research and development of HSP105 in a joint research project with the National Cancer CenterAmount ¥537 million (unallocated amount as of 28 February 2026: ¥226 million) / Scheduled timing of expenditures July 2020 to September 2027
Expenses related to the research and development of BAR-T technology in a joint research project with Kyoto Prefectural University of MedicineAmount ¥53 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures July 2020 to December 2022
Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failureAmount ¥170 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures December 2022 to March 2023
Working capital for headquarters operationsAmount ¥152 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures December 2022 to March 2023
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Series 15: 70,000 warrants (all fully exercised); Series 16: 164,000 warrants (all fully exercised)
Impact on Business Performance
The impact on results for the fiscal year ending September 2026 is immaterial
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of warrants by third-party allotment (Series 15 warrants and Series 16 warrants) |
| Number of shares to be issued or disposed of | Series 15 warrants: 7,000,000 shares; Series 16 warrants: 16,400,000 shares (all warrants fully exercised) |
| Amount of funds to be raised | Series 15 warrants: ¥398 million; Series 16 warrants: ¥1,463 million. Estimated net proceeds: Not disclosed |
| Specific use of funds | Details Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failure / Amount ¥226 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures October 2019 to September 2021, Details Development expenses for regenerative medicine products, including glycan-modified T cells / Amount ¥100 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures October 2020 to July 2025, Details Expenses related to the development of regenerative medicine products / Amount ¥71 million (unallocated amount as of 28 February 2026: ¥50 million) / Scheduled timing of expenditures August 2025 to September 2027, Details Expenses related to the development of regenerative medicine products / Amount ¥551 million (unallocated amount as of 28 February 2026: ¥551 million) / Scheduled timing of expenditures August 2025 to September 2027, Details Expenses related to the research and development of HSP105 in a joint research project with the National Cancer Center / Amount ¥537 million (unallocated amount as of 28 February 2026: ¥226 million) / Scheduled timing of expenditures July 2020 to September 2027, Details Expenses related to the research and development of BAR-T technology in a joint research project with Kyoto Prefectural University of Medicine / Amount ¥53 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures July 2020 to December 2022, Details Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failure / Amount ¥170 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures December 2022 to March 2023, Details Working capital for headquarters operations / Amount ¥152 million (unallocated amount as of 28 February 2026: ¥0 million) / Scheduled timing of expenditures December 2022 to March 2023 |
| Number of Stock Acquisition Rights | Series 15: 70,000 warrants (all fully exercised); Series 16: 164,000 warrants (all fully exercised) |
| Impact on Business Performance | The impact on results for the fiscal year ending September 2026 is immaterial |
Items this document does not state (22)
Issue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The scheduled expenditure periods were changed following a review of the development schedule and efforts to control expenditures.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.